Fibrinogen (factor I) and D-dimer are critical laboratory parameters in the assessment of hemostatic function. Fibrinogen is the final substrate of the coagulation cascade, while D-dimer is a marker of fibrin degradation and clot turnover. Together with the PT and aPTT, they form the core coagulation profile.
Fibrinogen Structure and Function
Fibrinogen is a 340 kDa glycoprotein synthesized by the liver, composed of three pairs of polypeptide chains (Aα, Bβ, γ) arranged as a dimer. It circulates at a normal plasma concentration of 200–450 mg/dL (5.9–13.2 µmol/L). In the final step of the coagulation cascade, thrombin cleaves fibrinopeptides A and B from fibrinogen, exposing polymerization sites. Fibrin monomers spontaneously polymerize, and factor XIIIa (activated by thrombin) cross-links the polymers to form a stable, insoluble fibrin clot. Fibrinogen also bridges platelet GPIIb/IIIa receptors during aggregation in primary hemostasis.
Fibrinogen Assays
The Clauss method is the gold standard for fibrinogen measurement. Citrated plasma is diluted and a high concentration of thrombin is added; the clotting time is inversely proportional to fibrinogen concentration. Results are read against a calibrated standard. The Clauss method is accurate in most clinical situations but can be falsely prolonged (low apparent fibrinogen) by direct thrombin inhibitors (argatroban, bivalirudin), high heparin levels, or certain paraproteins. The PT-derived method estimates fibrinogen from the change in light transmission during PT measurement. It is less accurate, especially in dysfibrinogenemia or with interference, but widely used as a screening tool. Immunologic assays (ELISA, nephelometry) measure fibrinogen antigen and are used to distinguish hypofibrinogenemia (low antigen and activity) from dysfibrinogenemia (normal antigen, low activity).
Clinical Interpretation of Fibrinogen
Hypofibrinogenemia (< 200 mg/dL) occurs in disseminated intravascular coagulation (consumption, DIC), massive hemorrhage (consumption and dilution), liver disease (decreased synthesis), and rare congenital disorders (afibrinogenemia, hypofibrinogenemia). Spontaneous bleeding risk rises below 100 mg/dL. Hyperfibrinogenemia (> 450 mg/dL) is an acute-phase reactant increased in infection, inflammation (CRP paralleling), malignancy, pregnancy, and cardiovascular disease. Elevated fibrinogen is an independent risk factor for thrombosis and coronary artery disease. Fibrinogen replacement (cryoprecipitate or fibrinogen concentrate) is indicated for significant bleeding with hypofibrinogenemia, typically targeting fibrinogen > 150 mg/dL.
D-Dimer: Structure and Formation
D-dimer is a specific fibrin degradation product generated when plasmin cleaves cross-linked fibrin. Unlike fibrinogen degradation products (FDPs), which can arise from both fibrin and fibrinogen, D-dimer specifically indicates that thrombin has generated fibrin, factor XIII has cross-linked it, and plasmin has degraded it — making D-dimer a marker of actual clot formation and turnover. D-dimer fragments are heterogeneous, ranging from 180 to over 10,000 kDa.
D-Dimer Assays
D-dimer is measured quantitatively (immunoturbidimetric, ELISA) or semi-quantitatively (latex agglutination). The two main assay types are: quantitative rapid ELISA (e.g., VIDAS D-Dimer, BioMérieux) — sensitive, specific, reference method for VTE exclusion; and immunoturbidimetric assays (e.g., Tina-quant, STA-Liatest) — widely used on automated coagulation analyzers. Results are reported in fibrinogen equivalent units (FEU, ng/mL) or D-dimer units (ng/mL). The lack of international standardization means each assay has its own cutoff, and results from different assays cannot be directly compared. The typical upper reference limit is approximately 500 ng/mL FEU, though age-adjusted cutoffs (patient’s age × 0.1 mg/L for patients > 50 years) improve specificity in elderly patients.
Clinical Use of D-Dimer
The primary use of D-dimer is ruling out venous thromboembolism (VTE). A negative D-dimer (< cutoff, with a high-sensitivity assay) effectively excludes deep vein thrombosis and pulmonary embolism in patients with low or moderate pre-test probability (Wells score). Age-adjusted cutoffs reduce false positives in older patients. D-dimer is also used in the diagnosis of disseminated intravascular coagulation (DIC), where markedly elevated D-dimer is a key ISTH criterion. Other causes of elevated D-dimer include pregnancy, recent surgery or trauma, malignancy, infection, liver disease, advanced age, and hospitalization. D-dimer has limited specificity and should never be used in isolation for diagnosis — it must be combined with clinical probability assessment and imaging when indicated.
Disseminated Intravascular Coagulation
DIC is a systemic thrombohemorrhagic syndrome characterized by widespread activation of coagulation, consumption of platelets and clotting factors, and secondary fibrinolysis. Laboratory findings include thrombocytopenia (platelet count), prolonged PT and aPTT, low fibrinogen, and markedly elevated D-dimer. The ISTH DIC scoring system assigns points based on platelet count, PT prolongation, fibrinogen level, and D-dimer (or FDP), with a score ≥ 5 indicating overt DIC. DIC is never a primary diagnosis — its underlying cause (sepsis, trauma, malignancy, obstetrical complication) must be identified and treated.
